A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

BACKGROUND: Mantle cell lymphoma accounts for 6% of all B-cell lymphomas and is generally incurable. It is characterized by the translocation t(11;14) leading to cyclin D1 over-expression. Cyclin D1 is downstream of the mammalian target of rapamycin threonine kinase and can be effectively blocked by...

Full description

Saved in:
Bibliographic Details
Main Authors: Renner, Christoph, Zinzani, Pier Luigi, Gressin, Rémy, Klingbiel, Dirk, Dietrich, Pierre-Yves, Hitz, Felicitas, Bargetzi, Mario, Mingrone, Walter, Martinelli, Giovanni, Trojan, Andreas, Bouabdallah, Krimo, Lohri, Andreas, Gyan, Emmanuel, Biaggi, Christine, Cogliatti, Sergio, Bertoni, Francesco, Ghielmini, Michele, Brauchli, Peter, Ketterer, Nicolas
Format: Artigo
Language:Inglês
Published: Ferrata Storti Foundation 2012
Subjects:
Original Articles and Brief Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3396682/
https://ncbi.nlm.nih.gov/pubmed/22315486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.053173
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items